Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04429542|
Recruitment Status : Recruiting
First Posted : June 12, 2020
Last Update Posted : September 29, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Head and Neck Squamous Cell Carcinoma Squamous Cell Carcinoma of Anal Canal Colorectal Cancer Squamous Cell Carcinoma of the Lung EGFR Amplification Epithelial Ovarian Cancer Pancreas Cancer Cutaneous Squamous Cell Carcinoma Head and Neck Neoplasms Carcinoma, Squamous Cell Squamous Cell Carcinoma of Head and Neck||Drug: BCA101 Drug: Pembrolizumab||Phase 1|
This is a Phase 1/1b, open-label study, which consists of dose escalation parts (Part A) followed by expansion cohorts (Part B) for both single agent BCA101 and combination BCA101 plus pembrolizumab.
The study population in dose escalation (Part A) of single agent BCA101 consists of subjects with EGFR-driven advanced solid tumors refractory to standard of care or for whom no standard of care is available. Dose escalation (Part A) of combination BCA101 and pembrolizumab consists of subjects with either Squamous Cell Carcinoma of the Head and Neck (HNSCC) or Squamous Cell Carcinoma of the Anal Canal (SCCAC) whose tumors are refractory to standard of care or for whom no standard of care is available.
Once the maximum tolerated dose (MTD) / recommended dose (RD) of single agent BCA101 is determined, the study will continue with expansion cohorts (Part B) with select tumor types. Expansion cohorts for single agent BCA101 will include cutaneous squamous cell carcinoma. Planned expansion cohorts for the combination of BCA101 and pembrolizumab include: 1) HNSCC and 2) SCCAC.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||292 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors|
|Actual Study Start Date :||June 1, 2020|
|Estimated Primary Completion Date :||December 31, 2023|
|Estimated Study Completion Date :||June 1, 2024|
Experimental: BCA101 Monotherapy
Route: IV Infusion Frequency: QW Current Dose: 1500mg
EGFR/TGFβ fusion monoclonal antibody
Experimental: BCA101 + pembrolizumab
Route: IV Infusion Frequency: Q3W Dose: 200mg
EGFR/TGFβ fusion monoclonal antibody
- Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs [ Time Frame: 24 months ]Incidence and severity of AEs and SAEs
- Tolerability of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs [ Time Frame: 24 months ]Incidence and severity of AEs and SAEs
- Incidence of Dose Limiting Toxicities (DLTs) [ Time Frame: 21 days ]Incidence of DLTs during the first cycle of treatment with BCA101 monotherapy or the combination of BCA101 and pembrolizumab.
- Objective Response Rate [ Time Frame: 24 months ]Determine objective response rate in each part of the study, per RECIST v1.1 and iRECIST
- Clinical Benefit Rate [ Time Frame: 24 months ]Determine clinical benefit rate in each part of the study, per RECIST v1.1 and iRECIST
- Progression free survival [ Time Frame: 24 months ]Determine PFS in each part of the study, per RECIST v1.1 and iRECIST
- Duration of Response [ Time Frame: 24 months ]Determine duration of response in each part of the study, per RECIST v1.1 and iRECIST
- Overall Survival [ Time Frame: 24 months ]Determine survival rates in each part of the study.
- AUC of BCA101 and pembrolizumab [ Time Frame: 24 months ]AUC
- Cmax of BCA101 and pembrolizumab [ Time Frame: 24 months ]Cmax
- Tmax of BCA101 and pembrolizumab [ Time Frame: 24 months ]Tmax
- Concentration vs time profile of BCA101 and pembrolizumab [ Time Frame: 24 months ]Ctrough
- Half-life of BCA101 and pembrolizumab [ Time Frame: 24 months ]Half-life
- Immunogenicity of BCA101 and pembrolizumab [ Time Frame: 24 months ]Incidence and titer of anti-drug-antibodies
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patient must have measurable disease amendable to biopsy and be willing to undergo both a pre-treatment and on-treatment biopsy, as well as provide archival tumor if available from the primary tumor (a paraffin embedded tumor tissue block sufficient to obtain at least 10 sections of 4 to 5 micrometer thickness).
- Patient must have a performance status of ≤1 on the Eastern Cooperative Oncology Group Performance Scale.
- Patients must have evaluable or measurable disease (computed tomography [CT]/magnetic resonance imaging [MRI] scans performed within 21 days before the screening visit are acceptable) demonstrating measurable disease, i.e., at least 1 unidimensional measurable lesion as defined by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1) and Immune Response Evaluation Criteria in Solid Tumors (iRECIST).
- Tumor eligibility:
PART B (Cohort expansion):
i. Single agent BCA101 - patients with the following tumor type will be eligible:
• Expansion Cohort 1: Cutaneous Squamous Cell Carcinoma (CSCC) - i. patients must have received (or been intolerant to or ineligible for) prior anti-PD-1 therapy in the metastatic or locally advanced setting.
ii. No prior history of treatment with anti-EGFR antibodies in the unresectable/metastatic setting (prior treatment with radiotherapy in the adjuvant setting is allowed).
ii. Combination BCA101 and pembrolizumab - patients with the following tumor types will be eligible: • Expansion Cohort 2: Head and Neck Squamous Cell Carcinoma (HNSCC), metastatic or unresectable, recurrent with a Combined Positive Score (CPS) equal to or greater than 1, as determined by an CLIA-approved laboratory test. Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx. Participants may not have a primary tumor site of nasopharynx (any histology).
i. Patients must have no prior systemic therapy administered in the recurrent or metastatic setting (with the exception of systemic therapy completed >6 months prior if given as part of multimodal treatment for locally advanced disease) or prior history of immune checkpoint inhibitors with the exception of neoadjuvant therapy (>6 months prior to study drug initiation). No prior history of anti-EGFR antibodies (with the exception of radiosensitizing agents and multimodal treatment for locally advanced disease).
ii. Patients must provide tissue for PD-L1 biomarker analysis from a core or excisional biopsy (fine needle aspirate is not sufficient): A newly obtained biopsy (within 90 days prior to start of study treatment) is preferred but an archival sample is acceptable.
iii. Patients must have results from testing of human papillomavirus (HPV) status for oropharyngeal cancer
• Expansion Cohort 3: Squamous Carcinoma of the Anal Canal (SCAC), locally advanced/unresectable or metastatic.
i. Patients must have received (or been intolerant to or ineligible for) at least 1 prior line of chemotherapy and received no more than 2 prior lines of systemic treatments for treatment of unresectable and/or metastatic disease. No prior history of immune checkpoint inhibitors.
- For Part A: Exposure to anti-EGFR antibodies within 4 weeks of the first dose of study drug.
- Prior treatment with any anti-TGFβ therapy.
- Prior history of Grade ≥ 2 intolerance or hypersensitivity reaction to cetuximab or other anti-EGFR therapy or other murine proteins or prior discontinuation of therapy in the setting of toxicity related to treatment.
- Pregnant or breastfeeding women.
- Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 14 days prior to the first dose of study drug, with the exception of topical, intranasal, intrabronchial, or ocular steroids.
- Known history of a hematologic malignancy (or solid tumor other than the ones indicated for this study), unless the patient has undergone potentially curative therapy with no evidence of that disease for 2 years. Does not include tumors with a negligible risk of metastasis or death (e.g. adequately treated basal or squamous cell carcinoma, stage 1 prostate cancer, or carcinoma in situ of the cervix or carcinoma in situ of the breast). Subjects enrolling in the CSCC cohort may have chronic lymphocytic leukemia as long as the patient is not on active treatment.
- Known cases of human immunodeficiency virus (HIV) are excluded if patients have a CD4+ T-cell (CD4+) count <250 cells/uL. To ensure that effective antiretroviral therapy (ART) is tolerated and that toxicities are not confused with investigational drug toxicities, trial participants should be on established ART for at least four weeks and have an HIV viral load less than 400 copies/mL prior to enrollment.
- Patients with chronic HBV infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment
- Patients with a known history of hepatitis C who have not completed curative antiviral treatment or have a HCV viral load above the limit of quantification
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04429542
|Contact: David Bohremail@example.com|
|United States, California|
|Moores Cancer Center UC San Diego Health||Not yet recruiting|
|La Jolla, California, United States, 92093|
|Contact: Debanjali Ghosh 858-246-0357 firstname.lastname@example.org|
|Principal Investigator: Assuntina Sacco, MD|
|Los Angeles, California, United States, 90095|
|Principal Investigator: Deborah Wong, MD|
|United States, Florida|
|H. Lee Moffitt Cancer Center and Research Institute, Inc||Recruiting|
|Tampa, Florida, United States, 33612|
|Contact: Hamza Elmohd 813-745-5554 Hamza.email@example.com|
|Principal Investigator: Jameel Muzaffar, MD|
|United States, Massachusetts|
|Dana Farber/Partners Cancer Care Inc||Recruiting|
|Boston, Massachusetts, United States, 02115|
|Contact: DFCI Clinical Trials Hotline 877-338-7425|
|Principal Investigator: Glen Hanna, MD|
|United States, New York|
|Memorial Sloan Kettering||Recruiting|
|New York, New York, United States, 10017|
|Principal Investigator: Paul Paik, MD|
|Columbia University Herbert Irving Comprehensive Cancer Center||Recruiting|
|New York, New York, United States, 10032|
|Contact: CPDM Nurse Navigator 212-342-5162 firstname.lastname@example.org|
|Principal Investigator: Richard Carvajal, MD|
|United States, Ohio|
|Cleveland, Ohio, United States, 44195|
|Contact 866-223-8100 TaussigResearch@ccf.org|
|United States, Pennsylvania|
|UPMC Hillman Cancer Center||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15232|
|Contact: Sarah Brodeur email@example.com|
|Principal Investigator: Dan Zanberg, MD|
|United States, South Carolina|
|Medical University of South Carolina, Hollings Cancer Center||Recruiting|
|Charleston, South Carolina, United States, 29425|
|Contact: Lilli Neal 843-792-8113 firstname.lastname@example.org|
|Contact: Carly Fecio 8437923479 email@example.com|
|Principal Investigator: John Kaczmar, MD|
|United States, Texas|
|MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Beryl Tross 713-745-0774 firstname.lastname@example.org|
|Principal Investigator: Van Morris, MD|
|Princess Margaret Cancer Centre||Recruiting|
|Toronto, Ontario, Canada, M5G 2M9|
|Principal Investigator: Phillippe Bedard, MD|
|Responsible Party:||Bicara Therapeutics|
|Other Study ID Numbers:||
KEYNOTE-E28 ( Other Identifier: Merck Sharp & Dohme LLC )
|First Posted:||June 12, 2020 Key Record Dates|
|Last Update Posted:||September 29, 2022|
|Last Verified:||September 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Carcinoma, Squamous Cell
Squamous Cell Carcinoma of Head and Neck
Carcinoma, Ovarian Epithelial
Head and Neck Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Neoplasms, Squamous Cell
Endocrine Gland Neoplasms
Genital Neoplasms, Female
Endocrine System Diseases
Respiratory Tract Neoplasms
Respiratory Tract Diseases
Antineoplastic Agents, Immunological